Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors.

Holstein, Sarah A; Bigelow, James C; Olson, Richard D; Vestal, Robert E; Walsh, Gerald M; Hohl, Raymond J

Holstein, Sarah A; Bigelow, James C; Olson, Richard D; Vestal, Robert E; Walsh, Gerald M; Hohl, Raymond J.

Affiliation

Holstein SA; Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton Sts, Buffalo, NY, 14263, USA, sarah.holstein@roswellpark.org.

Invest New Drugs ; 33(3): 594-602, 2015 Jun.

Article in En | MEDLINE | ID: mdl-25698442

Subject(s)

Anthracyclines/pharmacokinetics; Doxorubicin/analogs & derivatives; Neoplasms/drug therapy; Adult; Aged; Anthracyclines/chemistry; Anthracyclines/pharmacology; Anthracyclines/therapeutic use; Antineoplastic Agents/chemistry; Antineoplastic Agents/pharmacokinetics; Antineoplastic Agents/pharmacology; Antineoplastic Agents/therapeutic use; Cell Proliferation/drug effects; Demography; Dose-Response Relationship, Drug; Doxorubicin/chemistry; Doxorubicin/pharmacokinetics; Doxorubicin/pharmacology; Doxorubicin/therapeutic use; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms/pathology; Stroke Volume/drug effects; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Doxorubicin / Anthracyclines / Neoplasms Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Invest New Drugs Year: 2015 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google